Meeting
2022 ASCO Genitourinary Cancers Symposium
Genomic classification of clinically advanced major genito-urinary cancers (GUca) based on methylthioadenosine phosphorylase (MTAP) genomic loss.
Authors
Philippe E. Spiess
Moffitt Cancer Center & Research Institute, Tampa, FL
Philippe E. Spiess , Andrea Necchi , Petros Grivas , Gennady Bratslavsky , Joseph M Jacob , Oleksandr Kravtsov , Richard S.P. Huang , Vamsi Parini , Brennan Decker , Douglas I. Lin , Dean C. Pavlick , Natalie Danziger , Jeffrey S. Ross
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 164)
DOI
10.1200/JCO.2022.40.6_suppl.164
Abstract #
164
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Genomic classification of clinically advanced pancreatic ductal adenocarcinoma (PDAC) based on methylthioadenosine phosphorylase (MTAP) genomic loss (MTAP loss).
First Author: Natalie Ngoi
Poster
2023 ASCO Annual Meeting
CDH1-mutated clinically advanced urothelial bladder cancer (UBC): A genomic landscape and real-world clinical outcome study (RWCOS).
First Author: Kyle M Rose
Poster
2023 ASCO Genitourinary Cancers Symposium
Single and multi-hit PIK3CA short variant (SV) genomic alterations (GA) in clinically advanced prostate cancer (CAPC): A genomic landscape study.
First Author: Carla Miguel
Poster
2020 ASCO Virtual Scientific Program
Contrasting genomic profiles in post-systemic treatment metastatic sites (MET), pretreatment primary tumors (PT), and liquid biopsies (LB) of clinically advanced prostate cancer (PC).
First Author: Andrea Necchi